Aduro Biotech Inc. has received a milestone payment from Janssen Biotech Inc. for Aduro’s submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for ADU-741, a LADD immunotherapy product candidate for the treatment of prostate cancer. The IND will enable Janssen, Aduro’s license partner for ADU-741, to initiate a multi-center Phase 1 trial to evaluate the safety and immunogenicity of intravenous administration of ADU-741 in patients with metast...